Other oncology — Revenue
Eli Lilly Other oncology — Revenue decreased by 3.7% to $966.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 22.4%, from $789.00M to $966.00M. Over 4 years (FY 2021 to FY 2025), Other oncology — Revenue shows an upward trend with a 82.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful commercialization and market adoption of the company's secondary oncology pipeline, while a decrease may suggest product maturity or competitive pressure on non-flagship assets.
Detailed definition
This metric represents the total net sales generated from the company's oncology product portfolio excluding its primary...
Peer comparison
Peers in the pharmaceutical industry typically report this as a sub-segment of their oncology division, often categorized as 'Other Oncology' or 'Emerging Oncology' to distinguish from primary blockbuster therapies.
lly_segment_other_oncology_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $81.40M | $100.30M | $77.20M | $186.70M | $180.40M | $179.20M | $805.10M | $177.40M | $217.80M | $213.80M | $2.19B | $759.70M | $826.80M | $862.50M | $997.00M | $789.00M | $924.30M | $937.40M | $1.00B | $966.00M |
| QoQ Change | — | +23.2% | -23.0% | +141.8% | -3.4% | -0.7% | +349.3% | -78.0% | +22.8% | -1.8% | +922.4% | -65.2% | +8.8% | +4.3% | +15.6% | -20.9% | +17.1% | +1.4% | +7.0% | -3.7% |
| YoY Change | — | — | — | — | +121.6% | +78.7% | +942.9% | -5.0% | +20.7% | +19.3% | +171.5% | +328.2% | +279.6% | +303.4% | -54.4% | +3.9% | +11.8% | +8.7% | +0.6% | +22.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's other oncology — revenue?
- Eli Lilly (LLY) reported other oncology — revenue of $966.00M in Q1 2026.
- How has Eli Lilly's other oncology — revenue changed year-over-year?
- Eli Lilly's other oncology — revenue increased by 22.4% year-over-year, from $789.00M to $966.00M.
- What is the long-term trend for Eli Lilly's other oncology — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's other oncology — revenue has grown at a 82.3% compound annual growth rate (CAGR), from $330.50M to $3.65B.
- What does other oncology — revenue mean?
- The total revenue generated by the company's secondary or emerging cancer treatment products.